Atlas Trials

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Clinical trial NCT05630872 · COMPLETED

Trial details

NCT number
NCT05630872
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HIV-associated Tuberculosis
Start date
2024-02-13
Primary completion
2025-05-07
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.